Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.00 EUR
Change Today -0.04 / -0.99%
Volume 319.9K
VLA On Other Exchanges
Symbol
Exchange
Frankfurt
Vienna
EN Paris
OTC US
Vienna
As of 11:37 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

valneva se (VLA) Snapshot

Open
€4.04
Previous Close
€4.04
Day High
€4.07
Day Low
€3.97
52 Week High
06/2/14 - €5.75
52 Week Low
01/13/15 - €3.35
Market Cap
298.3M
Average Volume 10 Days
222.1K
EPS TTM
€-0.38
Shares Outstanding
74.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALNEVA SE (VLA)

Related News

No related news articles were found.

valneva se (VLA) Related Businessweek News

No Related Businessweek News Found

valneva se (VLA) Details

Valneva SE, a biotechnology company, develops, manufactures, distributes, and commercializes vaccines for infectious diseases worldwide. The company offer IXIARO/JESPECT, a vaccine to prevent Japanese encephalitis for travelers, military, and populations of endemic regions; JEEV, a vaccine to protect children and adults from Japanese encephalitis; and Dukoral, a vaccine against cholera and traveler’s diarrhea caused by enterotoxigenic escherichia coli. Its development programs include EB66 Pandemic Influenza, which has completed Phase 1 clinical trials in the United States and is in a new drug application Phase in Japan; Pseudomonas aeruginosa program, which is in Phase II/III development trial; and IC31 partnered programs comprising Phase I and II studies in the field of tuberculosis. The company also develops IC84, a vaccine candidate that is in a Phase I safety and immunogenicity study for the prevention of Clostridium difficile; and a multivalent protein subunit based vaccine candidate, which is nearing the completion of pre-clinical development and entering the IND process for the prevention of Lyme disease. In addition, it develops EB66 human programs and EB66 veterinary programs; and antibodies to treat infectious diseases and cancer. Further, the company offers EB66 cell line, a proprietary embryonic stem cell-based technology for the production of various human and veterinary viral and therapeutic vaccines; and IC31, a synthetic vaccine adjuvant that non-specifically enhances and shapes the immune response to specific antigenic components of vaccines through the targeted activation of the immune system. Valneva SE is headquartered in Lyon, France.

275 Employees
Last Reported Date: 03/21/15

valneva se (VLA) Top Compensated Officers

Chairman of the Management Board, Chief Execu...
Total Annual Compensation: €512.0K
President, Chief Business Officer and Member ...
Total Annual Compensation: €541.6K
Chief Financial Officer and Member of The Man...
Total Annual Compensation: €384.0K
Compensation as of Fiscal Year 2013.

valneva se (VLA) Key Developments

Valneva SE Announces Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Financial Guidance for 2015

Valneva SE announced audited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenues & grants of EUR 13,113,000 compared to EUR 11,640,000 a year ago. Net loss was EUR 11,520,000 compared to EUR 6,028,000 a year ago. LBITDA was EUR 3,754,000 compared to EUR 1,273,000 a year ago. Net operating cash out flow was EUR 7,846,000 compared to net operating cash inflow of EUR 1,130,000 a year ago. For the year, the company reported revenues & grants of EUR 42,429,000 compared to EUR 35,991,000 a year ago. Net loss was EUR 26,272,000 compared to EUR 24,110,000 a year ago. LBITDA was EUR 7,364,000 compared to EUR 11,709,000 a year ago. Net operating cash out flow was EUR 14,944,000 compared to net operating cash inflow of EUR 20,903,000 a year ago. The operating loss increased from EUR 20.9 million in 2013 to EUR 23.8 million in 2014. On a pro forma basis, the operating loss decreased by EUR 8.7 million, or 26.8%, from EUR 32.5 million in the year 2013 to EUR 23.8 million in the year 2014. This decrease was mainly due to cost synergies and prioritization of R&D activities in connection with the merger, including savings as a result of the disposal of the CMO business in the fourth quarter 2013. The purchases of intangible assets and property, plant and equipment (net of proceeds from sale of such assets) amounted to EUR 2.0 million in the year 2014 and to EUR 0.1 million in the year 2013. The company expects its 2015 revenues to be significantly increased to between approximately EUR 75 and 85 million by its recent acquisition of the Dukoral vaccine including a Nordic vaccine sales infrastructure and by revenue growth in its historical activities (revenue includes Dukoral product sales by the seller's group entities under transitional service agreement). Revenues of IXIARO® product sales are expected to grow to approximately EUR 30 million.

Valneva SE, 2014 Earnings Call, Mar 20, 2015

Valneva SE, 2014 Earnings Call, Mar 20, 2015

Valneva SE Signs Exclusive License Agreement with Jianshun Biosciences Ltd to Commercialise Valneva's EB66 Cell Line for Production of Human and Veterinary Vaccines in China

Valneva SE announced that it had signed an exclusive license agreement with Jianshun Biosciences Ltd. to commercialise Valneva's EB66 cell line for production of human and veterinary vaccines in China. Under the agreement, Jianshun Biosciences obtains the right to sublicense the EB66 cell line to Chinese vaccine producers whose future products based on the Valneva platform will be distributed on the territory of China only. Valneva will receive an upfront licence payment of EUR 2.5 million (USD 2.6 million). The company is entitled to further annual licence fees and royalties, including a EUR 500,000 payment in 2016, annual maintenance fees, and 50% of Jianshun Biosciences' revenue from sub-licensees. Valneva said it keeps full ownership of the EB66 platform and the right to license it outside China.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VLA:FP €4.00 EUR -0.04

VLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr342.00 DKK +3.00
Emergent Biosolutions Inc $30.61 USD -0.22
Green Cross Corp/South Korea 177,500 KRW -5,500.00
Virbac SA €236.85 EUR +2.85
Zoetis Inc $47.91 USD +0.86
View Industry Companies
 

Industry Analysis

VLA

Industry Average

Valuation VLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALNEVA SE, please visit www.valneva.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.